Associated Papers
The determination of the effect(s) of solute carrier family 22-member 2 (SLC22A2) haplotype variants on drug binding via molecular dynamic simulation systems.
Abrahams-October Z et al.
Scientific Reports, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.
Zazuli Z et al.
International Journal of Molecular Sciences, 2020
Genetic Diversity in Drug Transporters: Impact in African Populations.
Rajman I et al.
Clinical and Translational Science, 2020
Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition.
Lozano E et al.
Journal of Personalized Medicine, 2018
Genotypic and Phenotypic Factors Influencing Drug Response in Mexican Patients With Type 2 Diabetes Mellitus.
Sanchez-Ibarra HE et al.
Frontiers in Pharmacology, 2018
Characterization of ADME gene variation in 21 populations by exome sequencing.
Hovelson DH et al.
Pharmacogenetics and Genomics, 2017
Organic Cation Transporter 2 (OCT2/SLC22A2) Gene Variation in the South African Bantu-Speaking Population and Functional Promoter Variants.
Wilson NC et al.
Omics : a Journal of Integrative Biology, 2017
SLC22A2 - mapping genomic variations within South African indigenous and admixed populations.
Pearce B et al.
Drug Metabolism and Personalized Therapy, 2016
Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2016
Characterization of Disease-Associated Mutations in Human Transmembrane Proteins.
Molnár J et al.
Plos One, 2016
Single nucleotide polymorphisms of the SLC22A2 gene within the Xhosa population of South Africa.
Jacobs C et al.
Drug Metabolism and Pharmacokinetics, 2015
Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics.
Li J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
Lai Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.
Sissung TM et al.
Discovery Medicine, 2012
Screening of genetic variations of SLC15A2, SLC22A1, SLC22A2 and SLC22A6 genes.
Cheong HS et al.
Journal of Human Genetics, 2011
Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans.
Man M et al.
Journal of Clinical Pharmacology, 2010
Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin.
Chen Y et al.
Pharmacogenetics and Genomics, 2009
Genetic variants of the organic cation transporter 2 influence the disposition of metformin.
Song IS et al.
Clinical Pharmacology and Therapeutics, 2008
OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine.
Wang ZJ et al.
Pharmacogenetics and Genomics, 2008
Identification of the endogenous key substrates of the human organic cation transporter OCT2 and their implication in function of dopaminergic neurons.
Taubert D et al.
Plos One, 2007
Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population.
Kang HJ et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2007
Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics.
Katz DA et al.
Clinical Pharmacology and Therapeutics, 2006
Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants.
Fujita T et al.
Journal of Pharmaceutical Sciences, 2006
Membrane transporter proteins: a challenge for CNS drug development.
Girardin F
Dialogues in Clinical Neuroscience, 2006
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function.
Leabman MK et al.
Pharmacogenetics, 2002